Abstract 8500

Article

Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma

N. Bartlett, A. Forero-Torres, J. Rosenblatt, et al

Methods: A multicenter phase I weekly dosing, dose-escalation study was conducted in 34 patients (mean age 34) with refractory or recurrent Hodgkin lymphoma or systemic anaplastic large-cell lymphoma. Patients had received a median of 5 prior therapies and 62% had undergone autologous stem cell transplantation. The study was conducted to determine whether more frequent dosing might maximize antitumor activity with acceptable tolerability. SGN-35 was administered weekly at doses of 0.4–1.4 mg/kg (2-hour IV infusions). After two 28-day cycles (6 doses), patients with stable disease or better were eligible to continue SGN-35 treatment, and 27 were evaluable.

Results: Complete responses were reported in 10 patients; partial responses in 3, with stable disease in 11 and progressive disease in 3. Some reduction in tumor was found in 81% of patients. Median duration of response is at least 16 weeks (0.1+ to 27.1+ wk). Grade 3 neutropenia was reported in 3 patients and diarrhea, paresthesia, vomiting and leukopenia were each reported once. Among grade 4 events, neutropenia and hyperglycemia were each reported once. No grade 5 events were reported. Overall, the most common drug-related adverse events were nausea (26%), fatigue (24%), peripheral neuropathy (18%), and neutropenia (18%). Dose-limiting toxicities were reported in 1 patient at 1.0 mg/kg and in 2 patients at 1.4 mg/kg.

Conclusions: SGN-35 was generally well tolerated. It demonstrated robust antitumor activity in heavily pretreated CD30+ malignancies. The overall response rate (CR+PR) was 48% (13/27). Phase II studies are currently enrolling patients.

 

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content